Tilray initiated with an Overweight at Piper Jaffray. Piper Jaffray analyst Michael Lavery initiated coverage of Tilray with an Overweight rating and $90 price target. The analyst expects “strong” industry growth long-term, and believes Tilray is well positioned to be one of several likely winners given its relationships in medical, in the U.S., and in beverages. Lavery consider the company’s initial public offering lock-up expiry to be a near-term risk, especially with 77% insider ownership, but his 12-month Overweight view is based on its fundamental outlook. He pegs Tilray’s market opportunity at $15B-$50B in the near-term, and potentially $250B-$500B over the longer term.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.